JP2019529336A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529336A5
JP2019529336A5 JP2018566490A JP2018566490A JP2019529336A5 JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5 JP 2018566490 A JP2018566490 A JP 2018566490A JP 2018566490 A JP2018566490 A JP 2018566490A JP 2019529336 A5 JP2019529336 A5 JP 2019529336A5
Authority
JP
Japan
Prior art keywords
seq
disease
amino acid
acid sequence
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566490A
Other languages
English (en)
Japanese (ja)
Other versions
JP7029415B2 (ja
JP2019529336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/067067 external-priority patent/WO2018011073A1/en
Publication of JP2019529336A publication Critical patent/JP2019529336A/ja
Priority to JP2021164366A priority Critical patent/JP7244600B2/ja
Publication of JP2019529336A5 publication Critical patent/JP2019529336A5/ja
Application granted granted Critical
Publication of JP7029415B2 publication Critical patent/JP7029415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566490A 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法 Active JP7029415B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021164366A JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA201600416 2016-07-12
DKPA201600416 2016-07-12
DKPA201700005 2017-01-04
DKPA201700008 2017-01-04
DKPA201700008 2017-01-04
DKPA201700005 2017-01-04
DKPA201700179 2017-03-14
DKPA201700179 2017-03-14
PCT/EP2017/067067 WO2018011073A1 (en) 2016-07-12 2017-07-07 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021164366A Division JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2019529336A JP2019529336A (ja) 2019-10-17
JP2019529336A5 true JP2019529336A5 (enExample) 2021-11-18
JP7029415B2 JP7029415B2 (ja) 2022-03-03

Family

ID=60941665

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566490A Active JP7029415B2 (ja) 2016-07-12 2017-07-07 過リン酸化タウに特異的な抗体およびその使用方法
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021164366A Active JP7244600B2 (ja) 2016-07-12 2021-10-05 過リン酸化タウに特異的な抗体およびその使用方法

Country Status (41)

Country Link
US (6) US10472415B2 (enExample)
EP (2) EP3484916B1 (enExample)
JP (2) JP7029415B2 (enExample)
KR (1) KR102551971B1 (enExample)
CN (2) CN109618556B (enExample)
AU (2) AU2017295608B2 (enExample)
BR (1) BR112018004916A2 (enExample)
CA (1) CA3027561A1 (enExample)
CL (1) CL2019000082A1 (enExample)
CO (1) CO2018014325A2 (enExample)
CY (1) CY1123995T1 (enExample)
DK (1) DK3484916T3 (enExample)
DO (1) DOP2018000281A (enExample)
EC (1) ECSP19005417A (enExample)
ES (1) ES2862427T3 (enExample)
GE (1) GEP20217222B (enExample)
HR (1) HRP20210522T1 (enExample)
HU (1) HUE053679T2 (enExample)
IL (1) IL263530B2 (enExample)
JO (1) JOP20180117B1 (enExample)
LT (1) LT3484916T (enExample)
MA (2) MA45655B1 (enExample)
MX (1) MX2019000476A (enExample)
MY (1) MY197836A (enExample)
NI (1) NI201900003A (enExample)
NZ (1) NZ748983A (enExample)
PE (1) PE20190227A1 (enExample)
PH (1) PH12018502613B1 (enExample)
PL (1) PL3484916T3 (enExample)
PT (1) PT3484916T (enExample)
RS (1) RS61646B1 (enExample)
RU (1) RU2760875C1 (enExample)
SG (1) SG11201811015RA (enExample)
SI (1) SI3484916T1 (enExample)
SM (1) SMT202100194T1 (enExample)
SV (1) SV2019005807A (enExample)
TN (1) TN2018000419A1 (enExample)
TW (1) TWI747922B (enExample)
UA (1) UA124104C2 (enExample)
WO (1) WO2018011073A1 (enExample)
ZA (1) ZA201808329B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190136125A (ko) 2012-12-21 2019-12-09 국립연구개발법인 양자과학기술연구개발기구 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
CN110267985B (zh) * 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
JP2021512602A (ja) * 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. タウに特異的に結合する結合分子
EA202092088A1 (ru) * 2018-03-05 2020-11-13 Янссен Фармацевтика Нв Антитела анти-phf-тау и их применение
JP7293343B2 (ja) 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
WO2020193500A1 (en) 2019-03-28 2020-10-01 H. Lundbeck A/S Use of a ps396 assay to diagnose tauophaties
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2023008415A1 (ja) 2021-07-27 2023-02-02 STAND Therapeutics株式会社 ペプチドタグおよび当該ペプチドタグをコードする核酸
EP4392455A4 (en) * 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES
AU2024367338A1 (en) * 2023-10-24 2026-04-30 Ac Immune Sa Method of treating preclinicial alzheimer's disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009506302A (ja) 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ablによるタウのリン酸化
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US20100239570A1 (en) * 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
PE20140218A1 (es) 2010-10-07 2014-03-01 Ac Inmune S A Composicion farmaceutica
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
ES2600915T3 (es) * 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティWashington University タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
WO2014170549A1 (en) 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
JP6297071B2 (ja) 2014-01-23 2018-03-20 旭化成株式会社 ブロック共重合体組成物及び粘接着剤組成物
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Similar Documents

Publication Publication Date Title
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
Bussière et al. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance
JP6518727B2 (ja) 病理学的タウタンパク質の免疫学的標的化方法
Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies
Schroeder et al. Tau-directed immunotherapy: a promising strategy for treating Alzheimer’s disease and other tauopathies
RU2645259C2 (ru) Терапия и диагностика на основе белков тау-опосредуемой патологии при болезни альцгеймера
Shahaduzzaman et al. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson’s disease
Landlinger et al. Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease
RU2657438C2 (ru) Терапевтическое средство или профилактическое средство против деменции
Cynis et al. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
JP2012522754A5 (enExample)
SA520411188B1 (ar) جسم مضاد مربوط بالفا - ساينوكلين نشط
Doucet et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles
KR20110011596A (ko) 아밀로이드증의 치료 및 예방
JP2016501247A (ja) 抗Aβ抗体を使用して脳アミロイド斑を減少させる方法
JP2015517502A (ja) 卒中後の神経形成を促進するためのセマフォリン−4d結合分子の使用
JP6611858B2 (ja) D3から誘導されたd−エナンチオマーの新規ペプチド及びその使用
Teaktong et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology
CN104379167B (zh) 用于中风和缺血或缺血性病况的人抗体及其特异性结合序列
Levites et al. A human monoclonal IgG that binds Aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo
Levigoureux et al. Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice
Wang et al. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease
Li et al. Novel naturally occurring autoantibodies attenuate α‐synuclein pathology in a mouse model of Parkinson's disease
Kameshima et al. Correlation of Aβ deposition in the nasal cavity with the formation of senile plaques in the brain of a transgenic mouse model of Alzheimer's disease
CN101506231A (zh) 筛选具有抗淀粉样蛋白性质的化合物的方法